Gilead Sciences, Inc.
NEWS
The company allegedly used a foundation as a conduit to pay the copays of Medicare patients who were taking Letairis, Gilead’s pulmonary arterial hypertension drug.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 2, 2020.
The deal, announced Sunday, has been unanimously approved by the boards of directors of both companies.
Gilead Sciences and Jounce Therapeutics entered a discovery and development deal to exclusively license Jounce’s JTX-1811 immuno-oncology program.
The company indicates the agency requested data from the MANTA and MANTA-Ray trials before completing its review of filgotinib. Here’s more about it.
Maryland has become a key part of the strategy for Kite, a Gilead company, and its mission to find a cure for cancer.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
JOBS
IN THE PRESS